EA202191393A1 - Стабильная вакцина против clostridium difficile - Google Patents
Стабильная вакцина против clostridium difficileInfo
- Publication number
- EA202191393A1 EA202191393A1 EA202191393A EA202191393A EA202191393A1 EA 202191393 A1 EA202191393 A1 EA 202191393A1 EA 202191393 A EA202191393 A EA 202191393A EA 202191393 A EA202191393 A EA 202191393A EA 202191393 A1 EA202191393 A1 EA 202191393A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- clostridium difficile
- conjugate
- vaccine against
- synthetic saccharide
- against clostridium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
Abstract
Настоящее изобретение относится к синтетическому сахариду общей формулы (I), который относится к полисахариду клеточной поверхности PS-II Clostridium difficile и его конъюгату. Указанный синтетический сахарид, указанный конъюгат и фармацевтическая композиция, содержащая указанный синтетический сахарид или указанный конъюгат, являются применимыми для профилактики и/или лечения заболеваний, связанных с Clostridium difficile. Кроме того, синтетический сахарид общей формулы (I) является применимым в качестве маркера в иммунологических анализах для обнаружения антител к бактериям Clostridium difficile.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18207920 | 2018-11-22 | ||
PCT/EP2019/082331 WO2020104697A1 (en) | 2018-11-22 | 2019-11-22 | Stable vaccine against clostridium difficile |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191393A1 true EA202191393A1 (ru) | 2021-10-12 |
Family
ID=64650105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191393A EA202191393A1 (ru) | 2018-11-22 | 2019-11-22 | Стабильная вакцина против clostridium difficile |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230045939A1 (ru) |
EP (1) | EP3883944A1 (ru) |
JP (1) | JP7296459B2 (ru) |
KR (1) | KR20210094573A (ru) |
CN (1) | CN113166186A (ru) |
AU (1) | AU2019383549A1 (ru) |
BR (1) | BR112021008279A2 (ru) |
CA (1) | CA3120451A1 (ru) |
EA (1) | EA202191393A1 (ru) |
MX (1) | MX2021005949A (ru) |
WO (1) | WO2020104697A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024514531A (ja) * | 2021-04-02 | 2024-04-02 | マトリバックス,インコーポレーテッド | クロストリディオイデス・デフィシル(clostridiodes difficile)感染を処置する方法および組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0827406A1 (en) * | 1995-03-08 | 1998-03-11 | The Scripps Research Institute | Carbopeptoids and carbonucleotoids |
DE19648681A1 (de) * | 1996-11-25 | 1998-05-28 | Hoechst Ag | Antiadhäsive Benzoesäure-Derivate |
AU2008299536B2 (en) | 2007-09-11 | 2014-06-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium difficile |
US20130315959A1 (en) | 2010-12-24 | 2013-11-28 | Novartis Ag | Compounds |
AU2012224917A1 (en) | 2011-03-08 | 2013-09-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Oligosaccharides and oligosaccharide-protein conjugates derived from Clostridium difficile polysaccharide PS-II, methods of synthesis and uses thereof, in particular as a vaccine |
US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
US9328134B2 (en) * | 2013-02-22 | 2016-05-03 | Amgen Inc. | Carbohydrate phosphonate derivatives as modulators of glycosylation |
EP3331893B1 (en) * | 2015-08-05 | 2019-05-22 | Enterome | Mannose derivatives useful for treating pathologies associated with adherent e. coli |
-
2019
- 2019-11-22 JP JP2021528951A patent/JP7296459B2/ja active Active
- 2019-11-22 CA CA3120451A patent/CA3120451A1/en active Pending
- 2019-11-22 AU AU2019383549A patent/AU2019383549A1/en active Pending
- 2019-11-22 KR KR1020217018275A patent/KR20210094573A/ko not_active Application Discontinuation
- 2019-11-22 WO PCT/EP2019/082331 patent/WO2020104697A1/en unknown
- 2019-11-22 CN CN201980077346.2A patent/CN113166186A/zh active Pending
- 2019-11-22 US US17/296,194 patent/US20230045939A1/en active Pending
- 2019-11-22 EP EP19812940.5A patent/EP3883944A1/en active Pending
- 2019-11-22 BR BR112021008279-4A patent/BR112021008279A2/pt unknown
- 2019-11-22 MX MX2021005949A patent/MX2021005949A/es unknown
- 2019-11-22 EA EA202191393A patent/EA202191393A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
US20230045939A1 (en) | 2023-02-16 |
JP7296459B2 (ja) | 2023-06-22 |
JP2022516837A (ja) | 2022-03-03 |
WO2020104697A1 (en) | 2020-05-28 |
MX2021005949A (es) | 2021-07-06 |
KR20210094573A (ko) | 2021-07-29 |
CA3120451A1 (en) | 2020-05-28 |
BR112021008279A2 (pt) | 2021-08-03 |
EP3883944A1 (en) | 2021-09-29 |
AU2019383549A1 (en) | 2021-06-10 |
CN113166186A (zh) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
NZ734892A (en) | Amatoxin-antibody conjugates | |
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
CL2018000106A1 (es) | Moléculas de anticuerpo que se unen a cd45 | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
WO2018091740A3 (en) | Novel anti_cd137 antibodies and uses thereof | |
CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
BR112018015419A2 (pt) | degradantes seletivos de receptor de estrogênio e os usos dos mesmos | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
BR112018015238A2 (pt) | conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
BR112019005726A8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno | |
EA201591710A1 (ru) | Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство | |
MX2019004779A (es) | Composicion farmaceutica para tratamiento y/o prevencion de cancer. | |
EA201390874A1 (ru) | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение | |
BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
EA201991769A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК | |
BR112013031485A8 (pt) | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais | |
EA202092202A1 (ru) | Конструкции антител к ror | |
EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |